This shifts the status of AI tools for automated brain volumetry, potentially making the use of tools like mdbrain indispensable in the future. For other indications such as systematic oncological screening and cancer early detection methods, the potential value of AI tools is undeniable. But one question still remains: Is AI economically viable in the long term?
Reimbursement is imminent
The introduction of new CPT Category III codes for AI-supported quantitative MRI brain analysis in the USA, starting January 1, 2024, represents a significant milestone. This development provides a standardized framework for evaluating various neurological conditions, including dementia or multiple sclerosis, thereby improving patient care.
Another promising example is the progress in prostate cancer diagnostics. With the proven efficacy of mpMRIs, health insurance companies in Germany are now starting to cover the costs of AI tools, because AI plays a crucial role through automated longitudinal evaluations. These are particularly important for the efficient execution of large-scale screenings, as known from Active Surveillance.
Profitability beyond reimbursement
Both examples show that healthcare decision-makers understand the importance of integrating AI throughout the entire patient journey for large-scale integrated care. While direct reimbursements facilitate the adoption of technology, it is unrealistic to expect reimbursements for all relevant indications soon. Nevertheless, it is crucial for organizations, faced with increasing workloads and limited resources, to integrate AI now. The goal must be increased efficiency and improved diagnostic results, even without direct reimbursement.
An option that is becoming increasingly popular is billing individual health services directly to patients. If you are interested, please check here.
If you would like to learn more about integrating your tools into your daily workflow and achieving a positive ROI, schedule an appointment with our radiological expert, Marco Le Donne.
